There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report), Apellis Pharmaceuticals (APLS – Research Report) and MAIA Biotechnology, Inc. (MAIA – Research Report) with bullish sentiments.
Actinium Pharmaceuticals (ATNM)
In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $24.00. The company’s shares closed last Friday at $13.76, close to its 52-week high of $15.12.
According to TipRanks.com, Walsh is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $32.50 average price target, a 124.9% upside from current levels. In a report issued on February 6, Maxim Group also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
Apellis Pharmaceuticals (APLS)
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Apellis Pharmaceuticals, with a price target of $115.00. The company’s shares closed last Friday at $55.49.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $82.63 average price target, which is a 57.8% upside from current levels. In a report issued on February 19, Stifel Nicolaus also maintained a Buy rating on the stock with a $75.00 price target.
MAIA Biotechnology, Inc. (MAIA)
Noble Financial analyst Robert LeBoyer initiated coverage with a Buy rating on MAIA Biotechnology, Inc. today and set a price target of $14.00. The company’s shares closed last Friday at $4.53.
According to TipRanks.com, LeBoyer is a 3-star analyst with an average return of
Currently, the analyst consensus on MAIA Biotechnology, Inc. is a Moderate Buy with an average price target of $14.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATNM:
